Huang CJ, et al. - In patients with type 2 diabetes (T2D), researchers assessed the effects of blood glucose control when using antihyperglycemic agents with minimal hypoglycemia risk on cardiovascular outcomes. For this investigation, randomized controlled trials (RCTs) that compared the relative efficacy and safety of antidiabetic drugs with less hypoglycemia risk were researched in MEDLINE, Embase and the Cochrane Library up to January 27, 2018. It was observed that these newer T2D agents with less hypoglycemic hazard significantly decreased the risk of major adverse cardiovascular events (MACE) vs placebo. Findings suggested that the MACE reduction was correlated with hemoglobin A1c (HbA1c) reduction in a linear relationship.